Advocacy Update – March 2023: Federal Appropriations 101 and Why Advocacy Matters for Mito
On Tuesday, December 20, 2022, lawmakers unveiled their long-awaited $1.7 trillion government funding package. The package includes 12...
Read moreLatest News -Press Room
Reata Pharmaceuticals Announces FDA Approval of SKYCLARYS™ (Omaveloxolone) for Friedreich’s Ataxia. Learn What this Means for the Mito Community.
Cyclerion Therapeutics to Discuss CY6463 MELAS Clinical Data at a Webinar Hosted by United Mitochondrial Disease Foundation Company to...
Read moreResearch Update from 2015 UMDF Grant Recipient Sara Nowinski, PhD
In 2015, Sara Nowinski, PhD received a $70,000 grant award for her work “Characterizing the Function of the Atypical Mitochondrial Kinase...
Read moreAdvocacy Update – February 2023: Could ARPA-H Change the Research Landscape for Rare Diseases?
On Tuesday, December 20, 2022, lawmakers unveiled their long-awaited $1.7 trillion government funding package. The package includes 12...
Read moreAdvocacy Update – January 2023: What Does 2023 Hold for Mito Advocacy?
On Tuesday, December 20, 2022, lawmakers unveiled their long-awaited $1.7 trillion government funding package. The package includes 12...
Read moreAdvocacy Update – December 2022: Mito Research Funding Looks Headed for Renewal in Newly Unveiled Funding Bill
On Tuesday, December 20, 2022, lawmakers unveiled their long-awaited $1.7 trillion government funding package. The package includes 12...
Read more